Modality
ASO
MOA
PARPi
Target
SGLT2
Pathway
mTOR
AMLLGSCML
Development Pipeline
Preclinical
~Jan 2016
→ ~Apr 2017
Phase 1
Jul 2017
→ Jun 2028
Phase 1Current
NCT03231983
2,132 pts·CML
2022-08→2028-06·Recruiting
NCT07666452
1,386 pts·LGS
2017-07→2028-05·Recruiting
3,518 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-05-162.1y awayInterim· LGS
2028-06-212.2y awayInterim· CML
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1
Recruit…
P1
Recruit…
Catalysts
Interim
2028-05-16 · 2.1y away
LGS
Interim
2028-06-21 · 2.2y away
CML
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03231983 | Phase 1 | CML | Recruiting | 2132 | OS |
| NCT07666452 | Phase 1 | LGS | Recruiting | 1386 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevifotisoran | Neurocrine | Approved | CD47 |